Less intense therapy for early-stage breast cancer
Part of Cancer clinical trials.
This trial is testing a lower dose of treatment for women with small, early-stage breast cancer that is hormone-positive and has not spread to lymph nodes. The goal is to find out if it can be as effective as the standard treatment with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have a small tumor (2 cm or smaller) that hasn't spread to lymph nodes.
- Your cancer is hormone receptor-positive (ER positive) and HER2-negative.
- You have not had chemotherapy, radiation, or hormone therapy for this cancer before.
- You are generally healthy and able to do your daily activities.
- You have no other cancer or serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
This trial tests if a lower dose of the hormone therapy drug letrozole can work as well as the standard dose for people with early-stage hormone receptor-positive breast cancer. The lower dose may cause fewer side effects while still helping to prevent the cancer from coming back.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.